Trastuzumab, the first HER2-targeted agent approved for clinical use in breast cancer patients, demonstrated a significant overall survival improvement in HER2-positive early-stage and metastatic cancer patients in the early 2000s [48]. This evidence concerns the gene ERBB2 and metastatic malignant neoplasm.